Covered recipient · General Payments record
GIRIBALA R PATEL
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$1,356.41
76 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,356.41 | 76 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Celgene Corporation | $304.53 | 21 |
| Pharmacyclics LLC, An AbbVie Company | $216.47 | 19 |
| Novartis Pharmaceuticals Corporation | $185.67 | 6 |
| AstraZeneca Pharmaceuticals LP | $111.42 | 5 |
| Merck Sharp & Dohme LLC | $73.74 | 3 |
| Seagen Inc. | $69.31 | 2 |
| Gilead Sciences, Inc. | $54.34 | 3 |
| Amgen Inc. | $47.47 | 3 |
| Astellas Pharma US Inc | $40.51 | 2 |
| ARRAY BIOPHARMA INC | $39.82 | 2 |
| BeiGene USA, Inc. | $33.62 | 2 |
| E.R. Squibb & Sons, L.L.C. | $33.28 | 2 |
| Incyte Corporation | $29.48 | 1 |
| Lilly USA, LLC | $28.88 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.39 | 1 |
| Tolmar, Inc. | $23.49 | 1 |
| ABBVIE INC. | $23.46 | 1 |
| Rigel Pharmaceuticals, Inc. | $15.53 | 1 |
Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GIRIBALA R PATEL
NPI 1033106562 · CMS profile ID 138077
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
FULLERTON, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1033106562?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GIRIBALA R PATEL, NPI 1033106562, CMS profile ID 138077. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033106562?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). GIRIBALA R PATEL, NPI 1033106562, CMS profile ID 138077. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033106562?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- GIRIBALA R PATEL, NPI 1033106562, CMS profile ID 138077, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1033106562?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
76 matching records · $1,356.41 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–76 of 76.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Celgene Corporation | $5.69 | 05/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633199 | CMS |
| BeiGene USA, Inc. | $18.73 | 05/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051191597 | CMS |
| ARRAY BIOPHARMA INC | $22.39 | 05/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050347579 | CMS |
| Astellas Pharma US Inc | $20.39 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034099073 | CMS |
| Novartis Pharmaceuticals Corporation | $22.91 | 05/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992731387 | CMS |
| Celgene Corporation | $15.24 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633155 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $0.49 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292579 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $23.33 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292581 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $0.92 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292583 | CMS |
| Amgen Inc. | $18.09 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019917885 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.71 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633152 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.48 | 04/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015950725 | CMS |
| Lilly USA, LLC | $28.88 | 04/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031553541 | CMS |
| Celgene Corporation | $0.21 | 03/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633144 | CMS |
| Celgene Corporation | $18.30 | 03/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633147 | CMS |
| Celgene Corporation | $13.27 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633123 | CMS |
| Celgene Corporation | $12.40 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633127 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $25.08 | 02/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292577 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $0.59 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292575 | CMS |
| Celgene Corporation | $22.88 | 02/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633113 | CMS |
| Celgene Corporation | $25.21 | 01/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633097 | CMS |
| Astellas Pharma US Inc | $20.12 | 01/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033867945 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $0.85 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292571 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $22.34 | 01/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998292573 | CMS |
| Celgene Corporation | $22.59 | 01/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015633101 | CMS |
| Merck Sharp & Dohme LLC | $25.07 | 01/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048348649 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $357,078.70 | 35 |
| PY2024 | Principal investigator | $192,283.91 | 132 |
| PY2023 | Principal investigator | $836,696.14 | 27 |
| PY2022 | Principal investigator | $24,953.68 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
35 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,061.04 | 12/31/2025 | Non-covered Recipient Entity Providence Medical Foundation-Oncology | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926741 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,733.98 | 12/24/2025 | Non-covered Recipient Entity Translational Research In Oncology Us Inc | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223385907 |
| Principal investigator 1 | PFIZER INC. | $595.00 | 12/13/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228722988 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 12/08/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712892 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 12/08/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712976 |
| Principal investigator 1 | PFIZER INC. | $45,840.45 | 12/08/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228713058 |
| Principal investigator 1 | PFIZER INC. | $490.00 | 11/26/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228728955 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 11/24/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712890 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 11/24/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228713056 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,492.56 | 11/11/2025 | Non-covered Recipient Entity SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190304581 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $111.72 | 10/28/2025 | Non-covered Recipient Entity SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190304577 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 10/20/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334622 |
| Principal investigator 1 | BeOne Medicines Ltd. | $500.00 | 10/20/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334689 |
| Principal investigator 1 | BeOne Medicines Ltd. | $113.00 | 10/20/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334719 |
| Principal investigator 1 | BeOne Medicines Ltd. | $176.00 | 10/20/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334731 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 10/20/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334855 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $226.80 | 10/16/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223287021 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 10/16/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223287023 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,133.80 | 08/25/2025 | Non-covered Recipient Entity SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190304579 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 05/30/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326282 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,500.00 | 05/30/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190326306 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,000.00 | 05/30/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331263 |
| Principal investigator 1 | PFIZER INC. | $23,036.00 | 05/29/2025 | Non-covered Recipient Entity Providence Medical Foundation | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228765911 |
| Principal investigator 1 | BeiGene, Ltd. | $315.00 | 05/09/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320766 |
| Principal investigator 1 | BeiGene, Ltd. | $525.00 | 05/09/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320770 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 04/11/2025 | Non-covered Recipient Entity Providence Medical Foundation-Oncology | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926739 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,279.44 | 03/18/2025 | Non-covered Recipient Entity Saint Joseph Health System | A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma | No dispute reported | 06/30/2026 | 1235994107 |
| Principal investigator 1 | Eli Lilly and Company | $4,288.00 | 03/17/2025 | Non-covered Recipient Entity TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL INC | POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187891182 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $453.60 | 03/14/2025 | Non-covered Recipient Entity TRANSLATIONAL RESEARCH IN ONCOLOGY US INC | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223276363 |
| Principal investigator 1 | BeiGene, Ltd. | $10,173.00 | 02/28/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324378 |
| Principal investigator 1 | BeiGene, Ltd. | $735.00 | 02/24/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320052 |
| Principal investigator 1 | AstraZeneca UK Limited | $11,014.07 | 02/10/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | An Open-Label Multi-Center Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or who Previously Received Durvalumab in Other Protocols WAVE | No dispute reported | 06/30/2026 | 1185549917 |
| Principal investigator 1 | AstraZeneca UK Limited | $14,049.48 | 01/29/2025 | Non-covered Recipient Entity PROVIDENCE MEDICAL FOUNDATION | ROSY-D Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | No dispute reported | 06/30/2026 | 1185549919 |
| Principal investigator 1 | BeiGene, Ltd. | $420.00 | 01/22/2025 | Non-covered Recipient Entity Providence Medical Foundation | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190324242 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,684.56 | 01/09/2025 | Non-covered Recipient Entity SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190304583 |